Global GLP-1 Combination and Multi-agonist Drugs Market Strategic Research Report

Scope of the Report

The global GLP-1 Combination and Multi-agonist Drugs market size is predicted to grow from US$ 18,338 million in 2025 to US$ 61,932 million in 2032; it is expected to grow at a CAGR of 18.2% from 2026 to 2032.

GLP-1 combination and multi-agonist drugs are innovative medicines built around the GLP-1 pathway while also engaging GIP, glucagon, amylin or other metabolic targets to improve body weight, glucose control, fatty liver disease and cardiometabolic risk through synergistic mechanisms. The category includes dual agonists, tri-agonists, fixed-dose combinations and combination candidates, with evaluation focused on greater weight reduction, broader metabolic benefit, safety, dosing convenience and long-term adherence. In 2025, global GLP-1 Combination and Multi-agonist Drugs production reached approximately 320 million unit.The average gross profit margin of this product is 80%.

GLP-1 combination and multi-agonist drugs are among the most active innovation areas in obesity and metabolic disease. Dual- and tri-target mechanisms may further improve weight-loss efficacy beyond traditional GLP-1 therapy and expand use into diabetes, MASH and broader cardiometabolic risk management.

Industrial competition is concentrated among large global pharmaceutical companies and selected innovative biotechnology firms. Approved dual agonists have accelerated market education and physician adoption, while late-stage tri-agonists, GLP-1/glucagon dual agonists and amylin combinations may drive the next wave of differentiation.

Growth is influenced by clinical trial outcomes, long-term safety, capacity scale-up, drug pricing and payer coverage. Future market focus will shift toward the upper limit of efficacy, muscle-mass preservation, post-treatment weight management, liver metabolic improvement and integrated chronic disease care.

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 Combination and Multi-agonist Drugs market?

What factors are driving GLP-1 Combination and Multi-agonist Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1 Combination and Multi-agonist Drugs market opportunities vary by end market size?

How does GLP-1 Combination and Multi-agonist Drugs break out by Type, by Application?

This report presents a comprehensive overview of the global GLP-1 Combination and Multi-agonist Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• GIP/GLP-1 Dual Agonist
• GLP-1/Glucagon Dual Agonist
• Amylin/GLP-1 Combination
• GIP/GLP-1/Glucagon Tri-agonist
• GLP-1 Plus Small Molecule
• Other

Segment by Indication

• Obesity
• Type 2 Diabetes
• MASH
• Cardiometabolic Disease
• Other

Segment by Dosage Form

• Peptide Injection
• Long-acting Injection
• Oral Candidate
• Combination Kit
• Other

Segment by Application

• Obesity Clinics
• Endocrinology Departments
• Metabolic Disease Centers
• Clinical Trial Sites
• Hospital Pharmacies
• Retail Pharmacies
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global GLP-1 Combination and Multi-agonist Drugs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Obesity Clinics, Endocrinology Departments, Metabolic Disease Centers evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact